A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  • Haydon, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date15/12/22 → 15/07/24

Keywords

  • Clinical trial
  • melanoma
  • Metastatic cancer
  • second generation treatment